|Bid||144.11 x 900|
|Ask||144.20 x 800|
|Day's range||143.21 - 144.57|
|52-week range||94.59 - 144.57|
|Beta (3Y monthly)||0.85|
|PE ratio (TTM)||42.42|
|Earnings date||18 Jul 2019|
|Forward dividend & yield||0.68 (0.48%)|
|1y target est||144.33|
Examining Danaher Corporation's (NYSE:DHR) past track record of performance is an insightful exercise for investors...
The Zacks Analyst Blog Highlights: Berkshire Hathaway, salesforce, Danaher, Halliburton and American Airlines
Danaher (DHR) stands to gain from solid product portfolio, acquisitive nature and shareholder-friendly policy. High costs and debts as well as forex woes remain concerning.
Danaher Corporation (NYSE:DHR), a large-cap worth US$93b, comes to mind for investors seeking a strong and reliable...
Danaher (DHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher might be experiencing buyer’s remorse after GE biopharma competitors posted weak results. The purchase agreement might make remorse moot.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
General Electric's (GE) first-quarter 2019 results decline year over year due to weak sales performance and fall in margins. However, results surpass estimates.
Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to Danaher Corporation's (NYSE:DHR), to help you decide if the stock is worth further research...
The global science and technology company beat expectations in Q1. However, a pending acquisition caused Danaher to cut its full-year outlook.
Solid long-cycle businesses in U.S. defense, commercial aerospace, and warehouse and process automation drive Honeywell's (HON) Q1.
Danaher's (DHR) first-quarter 2019 results gain from sales growth and DBS initiatives. It lowers projection for 2019 to include the dilutive impact of the BioPharma buyout.
On a per-share basis, the Washington-based company said it had net income of 46 cents. Earnings, adjusted for pretax expenses and amortization costs, were $1.07 per share. The results exceeded Wall Street ...
Investing.com - Danaher (NYSE:DHR) reported first quarter earnings that Beat analysts' expectations on Thursday and revenue that topped forecasts.
Danaher's (DHR) first-quarter 2019 results to gain from solid product portfolio, innovative capabilities, Danaher Business System and acquired assets. Forex woes, tariffs and high costs drag.
Danaher (DHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.